Organization
Sumitomo Pharma Switzerland
8 clinical trials
1 abstract
Clinical trial
A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With EndometriosisStatus: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their OffspringStatus: Recruiting, Estimated PCD: 2033-05-01
Clinical trial
Congenital Athymia Patient Registry of RETHYMICStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination TherapyStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXStatus: Recruiting, Estimated PCD: 2028-05-31
Clinical trial
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for PregnancyStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Abstract
Evaluation of persistence and adherence for oral and injectable androgen deprivation therapies (ADT) in United States (US) patients with prostate cancer (PC).Org: Michigan Institute of Urology, Pfizer Inc., Sumitomo Pharma Switzerland, Analysis Group, Inc., Sumitomo Pharma America,
Clinical trial
A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-29
Clinical trial
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)Status: Active (not recruiting), Estimated PCD: 2024-12-31